*From the authors*:

We recently reported that current smokers and those with COPD had higher airway epithelial cell expression of the angiotensin-converting enzyme II (ACE-2) viral entry receptor \[[@C1]\]. We thus read with great interest the work of P. Russo and co-workers, which proposes a mechanism for this finding, namely that this upregulation is mediated by nicotine exposure specifically through the α7 subtype of nicotine acetylcholine receptors (α7-nAChR). While exposure to increasing concentrations of nicotine caused epithelial cells to increase ACE-2 levels, subsequent gene silencing of α7-nAChR appeared to significantly dampen this response. A secondary transcriptome sequencing analysis of our cohort (consisting of 42 subjects who underwent bronchoscopy for epithelial cell brushings \[[@C1]\]) reveals evidence in support of this hypothesis. We found that airway epithelial cell expression of *CHRNA7*, encoding α7-nAChR, was significantly correlated with the expression of *ACE2* (Pearson r=0.54, p=2.31×10^−8^) ([figure 1](#F1){ref-type="fig"}). There was significantly higher *CHRNA7* expression in those with COPD (2.75±0.73 *versus* 2.14±0.43 in those without COPD; p=1.47×10^−4^), with a trend towards higher expression in current smokers compared to former and never smokers (2.86±0.92 in current smokers, 2.35±0.57 in former smokers, and 2.27±0.45 in never smokers; p=6.16×10^−2^). *CHRNA7* was also negatively correlated with forced expiratory volume in 1 s percent predicted (Pearson r=−0.37, p=2.83×10^−4^). Interestingly, *CHRNA7* was positively if weakly correlated with body mass index (Pearson r=0.14, p=6.31×10^−3^), raising the intriguing possibility that nicotine receptor mediation of ACE-2 may also be related to why obese individuals have made up a considerable proportion of coronavirus disease 2019 (COVID-19) cases \[[@C2]\].

![Transcriptome profiles generated through RNA-Seq of airway epithelial cells demonstrated a significant positive correlation between *ACE2* and *CHRNA7* expression.](ERJ-01261-2020.01){#F1}

Together, these data further help to characterise the connections between airway epithelial ACE-2, and α7-nAChR, and the unique vulnerability of patients with COPD to severe COVID-19. α7-nAChR\'s widespread abundance in the human body, from neuronal tissue to immune cells to the lung and digestive tract, and its various roles in diseases such as schizophrenia \[[@C3]\], Alzheimer\'s disease \[[@C4]\] and Parkinson\'s disease \[[@C5]\] has meant that considerable work has already been done to target α7-nAChR as a therapeutic modality. As an example, α7-nAChR antagonists for the purpose of smoking cessation have long been proposed \[[@C6]\] and the idea of potentially repurposing these compounds for a pandemic with few therapeutic options currently available is certainly appealing. Whether α7-nAChR-selective antagonists, such as methyllycaconitine \[[@C7]\] and α-conotoxin \[[@C8]\], can meaningfully alter ACE-2 expression to prevent severe acute respiratory syndrome coronavirus 2 entry into the airway epithelium seems the next logical investigation in our furious pursuit for better therapeutics.
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